Use of antagonist [cetrorelix] versus agonist [triptorelin] GnRH [gonadotropin-releasing hormone] in oocyte recipient endometrium preparation

Trial Profile

Use of antagonist [cetrorelix] versus agonist [triptorelin] GnRH [gonadotropin-releasing hormone] in oocyte recipient endometrium preparation

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Feb 2013

At a glance

  • Drugs Cetrorelix (Primary) ; Triptorelin (Primary)
  • Indications Infertility
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Oct 2009 Primary endpoint of clinical pregnancy rate has been met.
    • 10 Oct 2009 Results have been presented at the 65th Annual Meeting of the American Society for Reproductive Medicine.
    • 07 Oct 2009 Actual end date (1 Oct 2009) added as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top